BCR and diffuse large B-cell lymphoma: The clinical outcome of tumor microenvironment/host inflammatory HR-DLBCL is quite similar to those of BCR/proliferation-DLBCL and OxPhos-DLBCL, with a 5-year survival of 54 to 60 % [40, 116, 134].